Head-To-Head Review: Silence Therapeutics (NASDAQ:SLN) versus Connect Biopharma (NASDAQ:CNTB)

Connect Biopharma (NASDAQ:CNTB) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Institutional and Insider Ownership

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Connect Biopharma and Silence Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$2.95 million	17.97	-$74.94 million	($1.19)	-0.71
Silence Therapeutics	$615,000.00	1,936.48	-$77.07 million	($1.28)	-15.45

Connect Biopharma has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Connect Biopharma and Silence Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	8	0	2.78
Silence Therapeutics	1	4	2	0	2.14

Connect Biopharma presently has a consensus target price of $5.88, indicating a potential upside of 597.33%. Silence Therapeutics has a consensus target price of $24.00, indicating a potential upside of 21.33%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Connect Biopharma is more favorable than Silence Therapeutics.

Profitability

This table compares Connect Biopharma and Silence Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	N/A	N/A
Silence Therapeutics	N/A	N/A	N/A

Volatility and Risk

Connect Biopharma has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.

Summary

Connect Biopharma beats Silence Therapeutics on 8 of the 11 factors compared between the two stocks.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.